GenomeKey
GenomeKey is dedicated to transforming diagnostics to prevent treatable infections from becoming fatal. They develop next-generation diagnostic devices that rapidly identify bacteria and antimicrobial resistance directly from patient blood, aiming to improve sepsis management worldwide. Their mission is to empower clinicians with fast, reliable, and comprehensive diagnostic tools to save lives, reduce healthcare costs, and preserve antibiotics for the future.
Industries
Nr. of Employees
small (1-50)
GenomeKey
Genomic Labs Ltd, Science Creates Old Market, Midland Road, Bristol, BS2 0JZ
Products
Next-generation benchtop in vitro diagnostic device for direct-from-blood bacterial ID and AMR profiling
A benchtop diagnostic instrument and associated workflows that detect and sequence bacterial pathogens directly from whole blood and generate comprehensive antimicrobial resistance profiles within hours to inform targeted therapy.
Next-generation benchtop in vitro diagnostic device for direct-from-blood bacterial ID and AMR profiling
A benchtop diagnostic instrument and associated workflows that detect and sequence bacterial pathogens directly from whole blood and generate comprehensive antimicrobial resistance profiles within hours to inform targeted therapy.
Services
Web-accessible platform that accepts sequence data, runs automated analysis for species identification and antimicrobial resistance detection, and generates reports. Offered in tiered plans (free, premium, enterprise).
Collaborative research and development engagements to refine sample prep, sequencing workflows, and analytical models for a clinical diagnostic device.
Collaborative clinical evaluations conducted in hospital settings to assess diagnostic performance and clinical utility of the device and workflows.
Web-accessible platform that accepts sequence data, runs automated analysis for species identification and antimicrobial resistance detection, and generates reports. Offered in tiered plans (free, premium, enterprise).
Collaborative research and development engagements to refine sample prep, sequencing workflows, and analytical models for a clinical diagnostic device.
Collaborative clinical evaluations conducted in hospital settings to assess diagnostic performance and clinical utility of the device and workflows.
Expertise Areas
- In vitro diagnostic (IVD) device development
- Direct-from-blood pathogen sequencing
- Host DNA depletion and sample enrichment
- Bioinformatics and ML-driven genome interpretation
Key Technologies
- Whole-genome sequencing (WGS)
- Host DNA depletion / bacterial DNA enrichment
- Machine learning for AMR prediction
- Automated bioinformatics pipelines
News & Updates
GenomeKey announced the appointment of Randy Pritchard as the new Chair of the Board, bringing over two decades of executive leadership experience.
GenomeKey received funding from the global non-profit CARB-X to develop a next-generation in vitro diagnostic device for bacterial identification directly from patient blood.
GenomeKey and Oxford Nanopore Technologies announced a collaboration to develop a new diagnostic tool for bloodstream infections.
Research on the status of antimicrobial resistance from leading health authorities.
GenomeKey announced the appointment of Randy Pritchard as the new Chair of the Board, bringing over two decades of executive leadership experience.
GenomeKey received funding from the global non-profit CARB-X to develop a next-generation in vitro diagnostic device for bacterial identification directly from patient blood.
GenomeKey and Oxford Nanopore Technologies announced a collaboration to develop a new diagnostic tool for bloodstream infections.
Research on the status of antimicrobial resistance from leading health authorities.